FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated by the Sponsor.

Conditions

Solid Tumor, Adult

Interventions

DRUG: FT538
DRUG: Cyclophosphamide
DRUG: Fludarabine
COMBINATION_PRODUCT: Monoclonal antibody - Dose Escalation
COMBINATION_PRODUCT: Monoclonal antibody - Dose Expansion

Sponsor

Fate Therapeutics